Mesenchymal stem cell and regenerative medicine: regeneration versus immunomodulatory challenges.
Law S., Chaudhuri S.
Clinical Trial on Tendon Injury, Ligament Injury, Cardiovascular Disease, Immune Modulation, published in Am J Stem Cells (2013) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Am J Stem Cells (2013)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 23671814
- PMCID
- PMC3636724
- Citations
- 93
Abstract (original English)
Mesenchymal Stem cells (MSC) are now presented with the opportunities of multifunctional therapeutic approaches. Several reports are in support of their self-renewal, capacity for multipotent differentiation, and immunomodulatory properties. They are unique to contribute to the regeneration of mesenchymal tissues such as bone, cartilage, muscle, ligament, tendon, and adipose. In addition to promising trials in regenerative medicine, such as in the treatment of major bone defects and myocardial infarction, MSC has shown a therapeutic effect other than direct hematopoiesis support in hematopoietic reconstruction. MSCs are identified by the expression of many molecules including CD105 (SH2) and CD73(SH3/4) and are negative for the hematopoietic markers CD34, CD45, and CD14. Manufacturing of MSC for clinical trials is also an important aspect as their differentiation, homing and Immunomodulatory properties may differ. Their suppressive effects on immune cells, including T cells, B cells, NK cells and DC cells, suggest MSCs as a novel therapy for GVHD and other autoimmune disorders. Since the cells by themselves are non-immunogenic, tissue matching between MSC donor and recipient is not essential and, MSC may be the first cell type able to be used as an "off-the-shelf" therapeutic product. Following a successful transplantation, the migration of MSC to the site of injury refers to t
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Effect of stem cell therapies on tendon-bone healing after anterior cruciate ligament reconstruction in animal models: Protocol for a systematic review and meta-analysis
Meta-analysis on Tendon Injury, Ligament Injury, Chronic Wound, published in PLoS One (2026) — summary generated from the PubMed abstract.
- 2026
PLoS One1 citations - Level ASystematic ReviewEurope PMC
Comparing Regenerative Biologics and Standard Pharmacotherapy for Chronic Rotator Cuff Tendinopathy: A Study of PRP, Cell-Based, and Peptide Interventions
Systematic Review on Tendon Injury, Rotator Cuff, Shoulder Pain, Chronic Inflammation, published in J Orthop Sports Med (2026) — summary generated from the PubMed abstract.
- 2026
J Orthop Sports Med - Level ASystematic ReviewEurope PMC
Tendon healing in the era of regenerative medicine: literature review
Systematic Review on Tendon Injury, published in Ann Transl Med (2026) — summary generated from the PubMed abstract.
- 2026
Ann Transl Med - Level AMeta-analysisEurope PMC
Surgical vs. non-surgical therapy for partial tears of the rotator cuff: a systematic review and meta-analysis of pooled studies with indirect comparison
Meta-analysis with a reported sample of 818 on Tendon Injury, Rotator Cuff, Shoulder Pain, published in BMC Musculoskelet Disord (2026) — summary generated from the PubMed abstract.
- 2026
- n = 818
BMC Musculoskelet Disord - Level AMeta-analysisEurope PMC
Efficacy of stem cell therapy for achilles tendon rupture: a systematic review and meta-analysis based on animal studies
Meta-analysis on Tendon Injury, published in Front Bioeng Biotechnol (2026) — summary generated from the PubMed abstract.
- 2026
Front Bioeng Biotechnol - Level ASystematic ReviewEurope PMC
Treatment options for Achilles tendinopathy: a scoping review of preclinical studies
Systematic Review on Tendon Injury, published in PeerJ (2025) — summary generated from the PubMed abstract.
- 2025
PeerJ4 citations